| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 13, 2025 |
| Accession Number: | 0001641172-25-009713 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/5/2023 | $2.00 | Buy | BTIG Research |
Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont., May 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today reported financial and operating results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $32.9 million, up 18%, compared to the prior year quarterGross margin of 61.5% compared to 62.1% for the prior year quarterNet income of $58,000 compared to a net lo
BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results. Conference Details:Conference Date: Monday, May 12, 2025Conference Time: 4:30 PM ETConference dial-in: 888-506-0062International dial
Third Quarter Revenue Growth of 12%Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 MillionRepresenting Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year periodGross margin of 58.4% compared to 61.3% for the prior year quarterNet loss of $5.0 mi
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors. "We are pleased to welcome Lori to our Board, marking another high-quality independent member addition," said Stavros G. Vizirgianakis, Chairman of Xtant's Board of Directors. "Her deep operations, information technologies, and marketing expertise will be of significant va
BELGRADE, Mont., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. "We are thrilled to have Mark rejoin the team as we reinvent Xtant," said Sean Browne, President and Chief Executive Officer of Xtant Medical. "In this newly created role, Mark will drive the modernization of our production, lead the optimization of our processes and operations, and support the diversification and development of new product lines. We look forward to Mark's contributio
SD - Xtant Medical Holdings, Inc. (0001453593) (Filer)
424B3 - Xtant Medical Holdings, Inc. (0001453593) (Filer)
EFFECT - Xtant Medical Holdings, Inc. (0001453593) (Filer)
Allogeneic Growth Factor Solution to Accelerate Bone Repair BELGRADE, Mont., May 28, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and wound care disorders, today announced the commercial launch of OsteoFactor Pro™, a naturally occurring cocktail of allogeneic growth factors engineered to improve bone healing and support surgical success across orthopedic and spine procedures. OsteoFactor Pro™ is a naturally derived, growth factor-rich formulation that enhances the biologic activity and regenerative potential of any orthobiologic scaffold. Its biphasic release profile—d
Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont., May 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today reported financial and operating results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $32.9 million, up 18%, compared to the prior year quarterGross margin of 61.5% compared to 62.1% for the prior year quarterNet income of $58,000 compared to a net lo
BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results. Conference Details:Conference Date: Monday, May 12, 2025Conference Time: 4:30 PM ETConference dial-in: 888-506-0062International dial
BTIG Research initiated coverage of Xtant Medical with a rating of Buy and set a new price target of $2.00
SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
SC 13D/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
3 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4/A - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)